Getting to the core of protein pharmaceuticals – comprehensive structure analysis by mass spectrometry

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Standard

Getting to the core of protein pharmaceuticals – comprehensive structure analysis by mass spectrometry. / Leurs, Ulrike; Mistarz, Ulrik Hvid; Rand, Kasper Dyrberg.

I: European Journal of Pharmaceutics and Biopharmaceutics, Bind 93, 2015, s. 95-109.

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Harvard

Leurs, U, Mistarz, UH & Rand, KD 2015, 'Getting to the core of protein pharmaceuticals – comprehensive structure analysis by mass spectrometry' European Journal of Pharmaceutics and Biopharmaceutics, bind 93, s. 95-109. https://doi.org/10.1016/j.ejpb.2015.03.012

APA

Leurs, U., Mistarz, U. H., & Rand, K. D. (2015). Getting to the core of protein pharmaceuticals – comprehensive structure analysis by mass spectrometry. European Journal of Pharmaceutics and Biopharmaceutics, 93, 95-109. https://doi.org/10.1016/j.ejpb.2015.03.012

Vancouver

Leurs U, Mistarz UH, Rand KD. Getting to the core of protein pharmaceuticals – comprehensive structure analysis by mass spectrometry. European Journal of Pharmaceutics and Biopharmaceutics. 2015;93:95-109. https://doi.org/10.1016/j.ejpb.2015.03.012

Author

Leurs, Ulrike ; Mistarz, Ulrik Hvid ; Rand, Kasper Dyrberg. / Getting to the core of protein pharmaceuticals – comprehensive structure analysis by mass spectrometry. I: European Journal of Pharmaceutics and Biopharmaceutics. 2015 ; Bind 93. s. 95-109.

Bibtex

@article{40033396ae574dfdbb6a65abc7a2e697,
title = "Getting to the core of protein pharmaceuticals – comprehensive structure analysis by mass spectrometry",
abstract = "Protein pharmaceuticals are the fastest growing class of novel therapeutic agents, and have been a major research and development focus in the (bio)pharmaceutical industry. Due to their large size and structural diversity, biopharmaceuticals represent a formidable challenge regarding analysis and characterization compared to traditional small molecule drugs. Any changes to the primary, secondary, tertiary or quaternary structure of a protein can potentially impact its function, efficacy and safety. The analysis and characterization of (structural) protein heterogeneity is therefore of utmost importance. Mass spectrometry has evolved as a powerful tool for the characterization of both primary and higher order structures of protein pharmaceuticals. Furthermore, the chemical and physical stability of protein drugs, as well as their pharmacokinetics are nowadays routinely determined by mass spectrometry.Here we review current techniques in primary, secondary and tertiary structure analysis of proteins by mass spectrometry. An overview of established top-down and bottom-up protein analyses will be given, and in particular the use of advanced technologies such as hydrogen/deuterium exchange mass spectrometry (HDX-MS) for higher-order structure analysis will be discussed. Modification and degradation pathways of protein drugs and their detection by mass spectrometry will be described, as well as the growing use of mass spectrometry to assist protein design and biopharmaceutical development.",
author = "Ulrike Leurs and Mistarz, {Ulrik Hvid} and Rand, {Kasper Dyrberg}",
year = "2015",
doi = "10.1016/j.ejpb.2015.03.012",
language = "English",
volume = "93",
pages = "95--109",
journal = "European Journal of Pharmaceutics and Biopharmaceutics",
issn = "0939-6411",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Getting to the core of protein pharmaceuticals – comprehensive structure analysis by mass spectrometry

AU - Leurs, Ulrike

AU - Mistarz, Ulrik Hvid

AU - Rand, Kasper Dyrberg

PY - 2015

Y1 - 2015

N2 - Protein pharmaceuticals are the fastest growing class of novel therapeutic agents, and have been a major research and development focus in the (bio)pharmaceutical industry. Due to their large size and structural diversity, biopharmaceuticals represent a formidable challenge regarding analysis and characterization compared to traditional small molecule drugs. Any changes to the primary, secondary, tertiary or quaternary structure of a protein can potentially impact its function, efficacy and safety. The analysis and characterization of (structural) protein heterogeneity is therefore of utmost importance. Mass spectrometry has evolved as a powerful tool for the characterization of both primary and higher order structures of protein pharmaceuticals. Furthermore, the chemical and physical stability of protein drugs, as well as their pharmacokinetics are nowadays routinely determined by mass spectrometry.Here we review current techniques in primary, secondary and tertiary structure analysis of proteins by mass spectrometry. An overview of established top-down and bottom-up protein analyses will be given, and in particular the use of advanced technologies such as hydrogen/deuterium exchange mass spectrometry (HDX-MS) for higher-order structure analysis will be discussed. Modification and degradation pathways of protein drugs and their detection by mass spectrometry will be described, as well as the growing use of mass spectrometry to assist protein design and biopharmaceutical development.

AB - Protein pharmaceuticals are the fastest growing class of novel therapeutic agents, and have been a major research and development focus in the (bio)pharmaceutical industry. Due to their large size and structural diversity, biopharmaceuticals represent a formidable challenge regarding analysis and characterization compared to traditional small molecule drugs. Any changes to the primary, secondary, tertiary or quaternary structure of a protein can potentially impact its function, efficacy and safety. The analysis and characterization of (structural) protein heterogeneity is therefore of utmost importance. Mass spectrometry has evolved as a powerful tool for the characterization of both primary and higher order structures of protein pharmaceuticals. Furthermore, the chemical and physical stability of protein drugs, as well as their pharmacokinetics are nowadays routinely determined by mass spectrometry.Here we review current techniques in primary, secondary and tertiary structure analysis of proteins by mass spectrometry. An overview of established top-down and bottom-up protein analyses will be given, and in particular the use of advanced technologies such as hydrogen/deuterium exchange mass spectrometry (HDX-MS) for higher-order structure analysis will be discussed. Modification and degradation pathways of protein drugs and their detection by mass spectrometry will be described, as well as the growing use of mass spectrometry to assist protein design and biopharmaceutical development.

U2 - 10.1016/j.ejpb.2015.03.012

DO - 10.1016/j.ejpb.2015.03.012

M3 - Review

VL - 93

SP - 95

EP - 109

JO - European Journal of Pharmaceutics and Biopharmaceutics

JF - European Journal of Pharmaceutics and Biopharmaceutics

SN - 0939-6411

ER -

ID: 132687616